Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study
Authors:
- 6 January 2023
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 26 (2) , 298-306
Abstract
Background Metachronous gastric cancer (MGC) may develop in patients undergoing curative endoscopic submucosal dissection for early gastric cancer. As gastritis and intestinal metaplasia are notable precursors to gastric cancer, we assessed MGC risk using the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM) systems. Methods This retrospective cohort study classified the OLGA and OLGIM stages for 916 patients who had undergone endoscopic submucosal dissection for early gastric cancer between 2005 and 2015. MGC development was followed up until 2020 and risk factors were evaluated using the Cox proportional hazards regression analysis. Results During a median follow-up of 94 months, MGC developed in 120 subjects. OLGA stages II ~ IV were significantly associated with increased MGC risk (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.05–3.19; HR 2.31, 95% CI 1.22–4.38; HR 2.36, 95% CI 1.16–4.78) in multivariable analysis, even after adjusting for the well-known positive predictor of Helicobacter pylori eradication. OLGIM stages II ~ IV also showed significant association (HR 2.86, 95% CI 1.29–6.54; HR 2.94, 95% CI 1.34–6.95; HR 3.64, 95% CI 1.60–8.29). 5-year cumulative incidence increased with each stage. Helicobacter pylori-eradicated patients with OLGIM stages 0 ~ II had significantly less MGC than non-eradicated patients (4.5% vs 11.8%, p = 0.022), which was not observed with OLGIM stages III ~ IV. Conclusions High OLGA and OLGIM stages are independent risk factors for metachronous gastric cancer, with the OLGIM staging system being a better predictor. Patients with OLGIM stages 0 ~ II are a subgroup that may benefit more from Helicobacter pylori eradication.Keywords
Funding Information
- National Research Foundation of Korea (#NRF-2022R1A2B5B01001430)
- Korean Society of Gastrointestinal Endoscopy (2021)
- SNUH Research Fund (#03-2022-0140)
This publication has 33 references indexed in Scilit:
- A Multicenter Retrospective Analysis of the Clinical Features of Pernicious Anemia in a Korean PopulationJournal of Korean Medical Science, 2013
- Optimal Biopsy Site for Helicobacter pylori Detection during Endoscopic Mucosectomy in Patients with Extensive Gastric AtrophyHelicobacter, 2012
- First‐degree relatives of patients with early‐onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasiaAlimentary Pharmacology & Therapeutics, 2012
- Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)Virchows Archiv, 2011
- The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritisGastrointestinal Endoscopy, 2010
- Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancerJournal of Gastroenterology and Hepatology, 2009
- Gastritis staging in clinical practice: the OLGA staging systemGut, 2006
- The Clinical Value of Taking Routine Biopsies from the Incisura Angularis During GastroscopyEndoscopy, 2005
- Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort studyGut, 2005
- Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancerInternational Journal of Cancer, 1999